Revolutionary Immunotherapy for Blood Cancers
Using chimeric antigen receptor technology to engineer a patient's own T cells to recognize and attack certain cancer cells
What is CAR-T Therapy?
CAR-T (Chimeric Antigen Receptor T-Cell) therapy is a breakthrough immunotherapy that uses genetic engineering to modify a patient's own T cells. T cells are collected, engineered to express chimeric antigen receptors that can precisely recognize and attack cancer cells, then expanded and infused back into the patient.
In simple terms, CAR-T therapy retrains selected immune cells so they can better recognize specific cancer targets. It is a highly personalized cell therapy that uses the patient's own immune system as part of the treatment strategy.
Back to Therapies Contact UsKey Advantages of CAR-T in China
China has established global leadership in CAR-T cell therapy
Cost-Effective
Often available at a lower cost than comparable treatment pathways in the United States
Faster Production
Automated cell preparation may shorten production timelines for eligible patients
Better Safety Profile
Specialist teams monitor cytokine release syndrome and other treatment-related risks closely
China's Global Leadership
China leads the world in CAR-T product development and clinical application
(More than US)
Blood Cancers
(Claudin18.2 target)
Rate
Treatment Indications
-
Acute Lymphoblastic Leukemia (ALL)
Particularly effective for relapsed/refractory B-cell ALL
-
B-Cell Non-Hodgkin Lymphoma
High response rates in diffuse large B-cell lymphoma
-
Multiple Myeloma
3 products approved specifically for this indication
-
Solid Tumors (Research Stage)
Claudin18.2 CAR-T showing promise in gastric cancer
Explore CAR-T Therapy Options
Contact us for personalized CAR-T treatment consultation
Speak with Our Care Team